Inhibitory Effects of Ginseng (Panax ginseng) Berry on Tumour Promotion and Inflammatory Ear Oedema Induced by TPA

Authors

  • Ken Yasukawa School of Pharmacy, Nihon University, Chiba 274-8555, Japan
  • Wan-Kyunn Whang College of Pharmacy, Chung-Ang University, Seoul 156-756, Korea
  • Sung-Kwon Ko Department of Oriental Medical Food & Nutrition, Semyung University, Chungcheongbuk 390-711, Korea

DOI:

https://doi.org/10.6000/1929-5634.2015.04.04.6

Keywords:

Cancer chemoprevention, antitumour-promoting activity, two-stage carcinogenesis, ginsenosides, Panax ginseng

Abstract

Cancer prevention is a major issue in the field of public health. Ethanol extracts of the ginseng berry were found to inhibit the inflammation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), a tumour promoter. The extracts also inhibited tumour promotion by TPA in the mouse skin two-stage carcinogenesis model. The major components, ginsenosides Rd (3) and Re (4), inhibited inflammation induced by TPA in mice, while protopanaxadiol (1) and protopanaxatriol (2), the aglycones of these ginsenosides, markedly inhibited TPA-induced inflammatory ear oedema in mice. The inhibitory effects of these compounds were more potent than those of indomethacin.

References

Yasukawa K. Medicinal and edible plants as caner preventive agents. In: Drug discovery research in pharmacognosy. Eds. Vallisuta O, Olimat SM. InTech, Rijeka, 2012; 181-208. http://dx.doi.org/10.5772/34545

Yasukawa K. Edible and medicinal mushrooms as promising agents in cancer. In: Drug discovery and development — From molecules to medicine. Eds. Vallisuta O, Olimat SM. InTech, Rijeka, 2015; 39-61. http://dx.doi.org/10.5772/59964

Bown D, Encyclopedia of herbs – & their uses –, Dorling Kindersley, London, 1995; 355.

Barnes J, Anderson LA, Phillipson JD. Herbal medicines. 3rd edition, Pharmaceutical Press, London, 2007; 325-336.

Kim HJ, Kim P, Shin CY. A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system. J Ginseng Res 2013; 37: 8-29. http://dx.doi.org/10.5142/jgr.2013.37.8

European Medicine Agency, Assessment report on Panax ginseng C.A. Meyer, radix. http://www.ema.europa.eu/docs/ en_GB/document_library/Herbal_-_HMPC_assessment_ report/2014/05/WC500167385.pdf.

Christensen LP. Ginsenosides: chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res 2007; 55: 1-99. http://dx.doi.org/10.1016/S1043-4526(08)00401-4

Chen X, Liu H, Lei X, Fu Z, Li Y, Tao L, Han R. Cancer chemopreventive and therapeutic activities of red ginseng. J Ethnopharmacol 1998; 60: 71-78. http://dx.doi.org/10.1016/S0378-8741(97)00133-5

Keum Y-S, Park K-K, Lee J-M, Chun K-S, Park JH, Lee SK, Kwon H, Surh Y-J. Antioxidant and anti-tumor promoting activities of the methanol extract of heat-processed ginseng. Cancer Lett 2000; 150: 41-48. http://dx.doi.org/10.1016/S0304-3835(99)00369-9

Ko SK, Bae HM, Cho OS, Im BO, Chung SH, Lee BY. Analysis of ginsenoside composition of ginseng berry and seed. Food Sci Biotechnol 2008; 17: 1379-1382. http://agris.fao.org/openagris/search.do?recordID=KR2009001089

Yasukawa K, Takido M, Takeuchi M, Nakagawa S. Effect of chemical constituents from plants on 12-O-tetradecanoylphorbol-13-acetate-induced inflammation in mice. Chem Pharm Bull (Tokyo) 1989; 37: 1071-1073. http://dx.doi.org/10.1248/cpb.37.1071

Kasahara Y, Kumaki K, Katagiri S, Yasukawa K, Yamanouchi S, Takido M, Akihisa T, Tamura T. Carthami Flos extract and its component, stigmasterol, inhibit tumor promotion in mouse skin two-stage carcinogenesis. Phytother Res 1994; 8: 327-331. http://dx.doi.org/10.1002/ptr.2650080603

Yasukawa K, Sun Y, Kitanaka S, Tomizawa N, Miura M, Motohashi S. Inhibitory effect of the Rhizomes of Alpinia officinarum on TPA-induced inflammation and tumor promotion in two-stage carcinogenesis in mouse skin. J Nat Med 2008; 62: 374-378. http://dx.doi.org/10.1007/s11418-008-0243-2

Yasukawa K, Okuda S, Nobushi Y. Inhibitory effect of gymnema (Gymnema sylvestre) leaves on tumour promotion in two-stage mouse skin carcinogenesis. Evidence-Based Complement Alternat Med 2014; 2014: 328684. http://dx.doi.org/10.1155/2014/328684

Lu P, Yin Y. Pulsed electric field treatment combined with commercial enzymes converts major ginsenoside Rb1 to miner ginsenoside Rd. Innovat Food Sci Emerg Technol 2014; 22: 95-101. http://dx.doi.org/10.1016/j.ifset.2013.12.010

Teng R, Li H, Chen J, Wang D, He Y, Yang C. Complete assignment of 1H and 13C NMR data for nine protopanaxatriol glycosides. Magn Reson Chem 2002; 40: 484-488. http://dx.doi.org/10.1002/mrc.1033

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2002; 357: 539-545. http://dx.doi.org/10.1016/S0140-6736(00)04046-0

Scott KA, Moore RJ, Arnott CH. An anti-tumor necrosis factor-a antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2003; 2: 445-451. http://mct.aacrjournals.org/content/2/5/445.long

Bowie A, O’Neill LA. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 2000; 59: 13-23. http://dx.doi.org/10.1016/S0006-2952(99)00296-8

Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-466. http://dx.doi.org/10.1038/nature02924

Mohan S, Epstein JB. Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. Oral Oncol 2003; 39: 537-546. http://dx.doi.org/10.1016/S1368-8375(03)00035-6

Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 2009; 9: 351-369. http://dx.doi.org/10.1016/j.coph.2009.06.020

Wu CF, Bi XL, Yang JY, Zhan JY, Dong YX, Wang JH, Wang JM, Zhang R, Li X. Differential effects of ginsenosides on NO and TNF-α production by LPS-activated N9 microglia. Int Immunopharmacol 2007; 7: 313-320. http://dx.doi.org/10.1016/j.intimp.2006.04.021

Jeong HG, Pokharel YR, Han EH, Kang KW. Induction of cyclooxygenase-2 by ginsenoside Rd via activation of CCAAT-enhancer binding proteins and cyclic AMP response binding protein. Biochem Biophys Res Commun 2007; 359: 51-56. http://dx.doi.org/10.1016/j.bbrc.2007.05.034

Song SB, Tung NH, Quang TH, Ngan NTT, Kim KE, Kim YH. Inhibition of TNF-α-mediated NF-κB transcriptional activity in HepG2 cells by dammarane-type saponins from Panax ginseng leaves. J Ginseng Res 2012; 36: 146-152. http://dx.doi.org/10.5142/jgr.2012.36.2.146

Kim DH, Chung JH, Yoon JS, Ha YM, Bae S, Lee EK, Jung KJ, Kim MS, Kim MK, Chung HY. Ginsenoside Rd inhibits the expressions of iNOS and COX-2 by suppressing NF-κB in LPS-stimulated RAW264.7 cells and mouse liver. J Ginseng Res 2013; 37: 54-63. http://dx.doi.org/10.5142/jgr.2013.37.54

Paul S, Shin HS, Kang SC. Inhibition of inflammations and macrophage activation by ginsenoside-Re isolated from Korean ginseng (Panax ginseng C. A. Meyer). Food Chem Toxicol 2012; 50: 1354-1361. http://dx.doi.org/10.1016/j.fct.2012.02.035

Lee I-A, Hyam SR, Jang S-E, Han MJ, Kim D-H. Ginsenoside Re ameliorates inflammation by inhibiting the binding of lipopolysaccharide to TLR4 on macrophages. J Agric Food Chem 2012; 60: 9595-9602. http://dx.doi.org/10.1021/jf301372g

Yun TK, Choi SY. A case-control study of ginseng intake and cancer. Int J Epidemiol 1990; 19: 871-876. http://dx.doi.org/10.1093/ije/19.4.871

Yun TK, Choi SY. Preventive effect of ginseng intake against various human cancers: a case-control study on 1987 pairs. Cancer Epidemiol Biomarkers Prev 1995; 4: 401-408. http://cebp.aacrjournals.org/content/4/4/401.long

Yun TK, Choi SY. Non-organ specific cancer prevention of ginseng: a prospective study in Korea. Int J Epidemiol 1998; 27: 359-364. http://dx.doi.org/10.1093/ije/27.3.359

Downloads

Published

2016-02-02

How to Cite

Yasukawa, K., Whang, W.-K., & Ko, S.-K. (2016). Inhibitory Effects of Ginseng (Panax ginseng) Berry on Tumour Promotion and Inflammatory Ear Oedema Induced by TPA. Journal of Nutritional Therapeutics, 4(4), 143–148. https://doi.org/10.6000/1929-5634.2015.04.04.6

Issue

Section

General Articles